Michal Golan Mashiach
CEO Edity Therapeutics
Michal Golan-Mashiach is the founder and CEO of Edity Therapeutics and Applied Genomics. Edity re-engineers immune cells to harness their power away from killing and to enable precise therapy. Golan-Mashiach holds a B.Sc. in Computer Science and MBA from Tel Aviv University in Israel, M.Sc. in Bioinformatics and Ph.D. in Systems-Biology from the Weizmann Institute of Science in Israel. Michal has more than 25 years of in academic and industrial experience in drug development genetics, gene-editing, bioinformatics, and computational biology.
Seminars
Tuesday 24th February 2026
Panel Discussion: Building Stronger Bridges Between Biotechs, Pharma & Investors
11:00 am
- Share how biotechs can present data and strategy in ways that help investors and pharma make faster, more confident decisions, reducing risk on both sides
- Highlight how pharma and investors can communicate expectations more clearly ensuring companies design studies and pipelines that are partner-ready
